Nemluvio (Nemolizumab)

Nemolizumab is a monoclonal antibody that binds to the interleukin‑31 receptor A (IL‑31RA). By blocking IL‑31 signaling, it interrupts the pathway that triggers itch and inflammatory responses in the skin, leading to symptom improvement.

The dosing regimen for Nemluvio is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. Specific dose amounts and intervals are individualized and should follow the prescriber’s instructions.

Safety data for Nemluvio in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To request Nemluvio, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Nemluvio targets the IL‑31 pathway, whereas many traditional systemic agents (e.g., cyclosporine, methotrexate) act more broadly on immune suppression. Compared with other biologics such as dupilumab, Nemluvio focuses specifically on itch reduction, offering a complementary mechanism for patients who need additional pruritus control.

Nemluvio must be stored in a refrigerated environment between 2 °C and 8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken to maintain product integrity.

Nemluvio is given as a subcutaneous injection. The injection is performed by a qualified healthcare professional, typically in a clinical setting, following the dosing schedule prescribed by the treating physician.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, serious infections that may require hospitalization, and rare hematologic abnormalities like neutropenia or thrombocytopenia. Patients should be monitored closely for any signs of these events.

Nemluvio is contraindicated in individuals with known hypersensitivity to nemolizumab or any of its excipients. Patients receiving live vaccines, or those with uncontrolled severe infections, should also avoid this therapy until the underlying issue is resolved.